drugset / Trial / NCT03820414
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
Phase 1
Completed
90 enrolled
Curevo Inc
Access to Advanced Health Institute (AAHI) · collabGreen Cross Corporation · collabMogam Biotechnology Research Institute · collab
RandomizedSequentialQuadruple-blindPrevention
Summary
The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.
Timeline
- Start
- 2019-01-03
- Primary completion
- 2020-04-04
- Completion
- 2020-04-30
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRV 101 | Vaccine | — | Intramuscular |